575. Safety and Immunogenicity of mRNA-1403, a Multivalent Norovirus mRNA Vaccine, in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.013
Abstract: Abstract Background Norovirus (NoV) is a leading cause of acute gastroenteritis worldwide and is associated with significant disease burden across all ages. Currently, there is no licensed NoV vaccine. NoV’s high genetic diversity coupled with… read more here.
Keywords: mrna 1403; inc employee; employee moderna; inc ... See more keywords
P-97. Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an Investigational Vaccine Against RSV, Given at 12 Months Following a Primary Dose in Adults Aged ≥ 50 Years
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.304
Abstract: Abstract Background mRNA-1345 is an investigational RSV vaccine that has demonstrated efficacy for the prevention of lower-respiratory tract disease in older adults. The duration of protection and need for revaccination have not yet been defined.… read more here.
Keywords: inc employee; employee moderna; inc; inc stocks ... See more keywords
P-102. Six-Month Safety, Durability, and Cross-Neutralization of the SARS-CoV-2 XBB.1.5-Containing Vaccine
Sign Up to like & getrecommendations! Published in 2025 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofae631.309
Abstract: Abstract Background Monovalent omicron XBB.1.5-containing vaccines were approved for use in 2023-2024 COVID-19 immunizations to better match emergent XBB variants. In an ongoing phase 2/3 study, the monovalent omicron XBB.1.5 vaccine (mRNA-1273.815) was previously shown… read more here.
Keywords: inc employee; employee moderna; inc; inc stocks ... See more keywords